Gene therapies for sickle cell disease: final evidence report

Gene therapies for sickle cell disease: final evidence report

Collection:
Health Policy and Services Research
Author(s):
Beaudoin, Francesca, author
Nikitin, Dmitriy, author
Campbell, Jonathan D., author
McKenna, Avery, author
Pearson, Steven D., author
Rind, David M., author
Thokala, P. (Praveen), author
Spackman, David Eldon, author
Contributor(s):
Institute for Clinical and Economic Review, issuing body.
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 21, 2023
Language(s):
English
Format:
Text
Subject(s):
Anemia, Sickle Cell -- therapy
Genetic Therapy
United States
Genre(s):
Technical Report
Abstract:
We reviewed the clinical effectiveness of lovotibeglogene autotemcel (lovo-cel) and exagamglogene autotemcel (exa-cel) versus standard of care for the treatment of severe sickle cell disease. We also intended to compare lovo-cel to exa-cel via any evidence directly comparing the two therapies or by indirect comparisons of key outcomes. We sought evidence on patient-important outcomes, including resolution of vaso-occlusive crisis, health-related quality of life, and adverse events.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file ( various pagings))
Illustrations:
Illustrations
NLM Unique ID:
9918697383806676 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/9918697383806676